Skip to Content

Not actual patients.

Revance’s therapeutic pipeline seeks to bring innovation to multiple indications in muscle movement and pain disorders.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

Therapeutics

FACTS, FIGURES, & TRENDS

$2.3 billion

Estimated global sales of neurotoxin for therapeutic use.1

12

Approved therapeutic indications for botulinum toxin Type A in the U.S. and hundreds of potential indications.1,2

3

Ongoing clinical trials for therapeutic indications of DaxibotulinumtoxinA for Injection.3,4,5

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

Daring to Make a Difference in Therapeutics

Our investigational neuromodulator product DaxibotulinumtoxinA for Injection is being evaluated in therapeutic indications, including cervical dystonia (Phase 3), upper limb spasticity (Phase 2), and plantar fasciitis (Phase 2), with plans to study migraine. Topline positive results for the cervical dystonia trial ASPEN-1 were announced in October 2020 and represent the first positive Phase 3 trial in the therapeutic neuromodulator category for Revance.​​

For the latest information regarding our clinical development programs, please see our public filings with Securities and Exchange Commissions or visit www.clinicaltrials.gov.

Not an actual patient.

Cervical Dystonia

Positive topline results from Revance's pivotal ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia, a debilitating neurologic disorder affecting the neck muscles, were announced in October 2020. The results demonstrate a potential advancement in the treatment paradigm for patients affected by cervical dystonia. The ASPEN-OLS Phase 3 open-label, long-term safety study results are expected in 2021.

Learn More

Plantar Fasciitis

In December 2019, Revance completed enrollment of its Phase 2 placebo-controlled clinical trial of DaxibotulinumtoxinA for Injection for the management of plantar fasciitis. Plantar fasciitis is characterized by inflammation and sharp, constant pain in the heel that can become incapacitating. The company expects to report topline results for the Phase 2 trial in fall of 2020.

Learn More

Adult Upper Limb Spasticity

The JUNIPER Phase 2 Trial for treatment of adult upper limb spasticity is currently underway. Upper limb spasticity is a form of movement disorder that presents as increased tone or stiffness of the muscles affecting a patient's ability to produce or control voluntary movement in the arms and hands. Revance expects to report topline results from the JUNIPER trial in first quarter of 2021.

Learn More

Migraine

Revance is also considering the use of DaxibotulinumtoxinA for Injection for migraines. Potential timing of clinical studies and the path forward is currently being evaluated.

Therapeutics Clinical Program Update

  • PRECLINICAL
  • PHASE 1
  • PHASE 2
  • PHASE 3

DaxibotulinumtoxinA for Injection — Therapeutics

Cervical Dystonia
PHASE 3 COMPLETE
Plantar Fasciitis
IN PHASE 2
Upper Limb Spasticity
IN PHASE 2
ASPEN-OLS Readout in 2021 Readout in Fall 2020 Readout in Early 2021

Publications

DaxibotulinumtoxinA for Injection is an investigational product. It is currently undergoing clinical studies for both therapeutic and aesthetic indications.

Learn More About Cervical Dystonia with Dr. Joseph Jankovic
  • Learn More About Cervical Dystonia with Dr. Joseph Jankovic
Revance Announces Top-Line Results for ASPEN-1
  • Revance Announces Top-Line Results for ASPEN-1

References

  1. 2019 (E) based on Decision Resources Group Therapeutic Botulinum Toxin Market Analysis Global 2019, November 2018

  2. Time Magazine, January 16, 2017, How BOTOX Became the Drug That’s Treating Everything. Available at: https://time.com/4623409/botox-drug-treating-everything/. Accessed April 2020

  3. Clinicaltrials.gov. US National Library of Medicine. Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity (JUNIPER). Available at: https://clinicaltrials.gov/ct2/show/NCT03821402. Accessed July 2019.

  4. Clinicaltrials.gov. US National Library of Medicine. Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) (ASPEN-1) Available at: https://clinicaltrials.gov/ct2/show/NCT03608397. Accessed July 2019.

  5. Clinicaltrials.gov. US National Library of Medicine. DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis. Available at: https://clinicaltrials.gov/ct2/show/NCT03825315. Accessed July 2019.

Career Opportunities

Do you have what it takes to join our team? Check out our Careers page and find out.

Learn More
Back to top